Novo Nordisk

Key Points Novo Nordisk is expecting earnings to decline in 2026. The company's GLP-1 pill has seen more demand than management expected. 10 stocks we like b...

Hims & Hers Health Inc. (NYSE:HIMS) has decided to cease offering its compounded semaglutide pill. Hims & Hers Explains Its Decision Hims & Hers' decision to st...

Hims & Hers Health (NYSE:HIMS) is facing heightened regulatory and legal scrutiny over its compounded semaglutide weight loss pill, launched as a lower cost alt...

Nate Becker 12m Hims to stop offering copy of Wegovy pill following FDA scrutiny Hims & Hers said it has decided to stop offering its newly launched copycat ver...

Novo Nordisk (NYSE:NVO) has moved to take legal and regulatory action against Hims & Hers Health over a compounded oral semaglutide pill linked to its obesity d...

Wegovy weight-loss pills Novo Nordisk Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month. Today, Novo Nordisk’s NOVO....

The market for obesity drugs may soon reach almost $100 billion. Over the past few years, Eli Lilly (LLY +3.54%) and Novo Nordisk (NVO +9.43%) have been domina...

Novo Nordisk A/S (NYSE:NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance and compounding conce...

Biotech and Pharma Hims & Hers Stock Drops. It May Be Losing Its Weight-Loss Battle With Novo. In this article NVO SPX HIMS LLY Shares in Novo Nordisk have tank...

The drugmaker is facing pricing pressures on its weight loss medications. Shares of Novo Nordisk (NVO +7.80%) were down over 20% this week as of this writing o...